Monitor for any subsequent conversion of this 13G to a 13D, which would signal activist intent. For now, the filing is routine post-IPO insider/VC ownership disclosure with no immediate trading implications.
Price Chart
Executive Summary
LAV Biosciences Fund V, L.P. and affiliated entities (LAV Fund VI, L.P., LAV Fund VI Opportunities, L.P., and Yi Shi) filed a Schedule 13G disclosing aggregate beneficial ownership of 11,858,655 shares of ADARx Pharmaceuticals common stock, representing 11.1% of shares outstanding as of September 30, 2026. This is a passive stake filing with no intent to influence control, filed shortly after ADARx's IPO in late September 2026. The filing confirms continued insider/VC ownership post-IPO and is neutral for the stock.
Key Financial Metrics
Key Facts
- LAV Biosciences Fund V, L.P. directly owns 11,243,179 shares (10.5% of outstanding).
- LAV Fund VI, L.P. directly owns 307,738 shares (0.3%).
- LAV Fund VI Opportunities, L.P. directly owns 307,738 shares (0.3%).
- Yi Shi is deemed indirect beneficial owner of the aggregate 11,858,655 shares (11.1%).
- Stake calculated based on 106,801,325 shares outstanding per the IPO prospectus filed September 28, 2026.
- Filing is passive (Rule 13d-1(d)) with no intent to influence control.
- This is an initial Schedule 13G filing post-IPO, not an amendment.
Financial Impact
Passive 11.1% stake disclosed; no financial impact from the filing itself.
Risk Factors
- Potential future conversion to 13D could signal a shift to activist stance.
- Insider selling by LAV entities post-lockup could create overhang.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001764435-26-000003 |
| Document: 0001764435-26-000003-index-headers.html | 0001764435-26-000003 |
| Document: 0001764435-26-000003-index.html | 0001764435-26-000003 |
| Document: 0001764435-26-000003.txt | 0001764435-26-000003 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | SC 13G | $17.63 $17.68 | ▲ +0.28% | ▼ −0.05% | $18.13 (+2.84%) |
Oct 5, 2026 22d ago | SC 13D | $18.58 $17.33 | ▼ −6.73% | ▼ −6.49% | $18.13 (−2.42%) |
Oct 2, 2026 25d ago | SC 13D | $19.05 $18.58 | ▼ −2.47% | ▼ −3.02% | $18.13 (−4.83%) |
Oct 1, 2026 26d ago | Press Release | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $18.13 (−0.66%) |
Oct 1, 2026 26d ago | SC 13G | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $18.13 (−0.66%) |
Sep 30, 2026 27d ago | Insider Cluster | $19.54 $18.25 | ▼ −6.60% | ▼ −7.34% | $18.13 (−7.22%) |
Sep 29, 2026 28d ago | Insider Cluster | $19.94 $19.54 | ▼ −2.01% | ▼ −2.18% | $18.13 (−9.08%) |
Sep 25, 2026 4w ago | 424B4 | $20.09 $20.64 | ▲ +2.71% | ▲ +2.90% | $18.13 (−9.76%) |
Sep 25, 2026 4w ago | EFFECT | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $18.13 (−6.30%) |
Sep 24, 2026 4w ago | Press Release | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $18.13 (−6.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers